| scholarly article | Q13442814 |
| P50 | author | Michael Boe Møller | Q40448280 |
| Karen Dybkær | Q41600604 | ||
| Jane Winter | Q43103944 | ||
| Ronald S Go | Q56990716 | ||
| Attilio Orazi | Q57839894 | ||
| Han van Krieken | Q61840699 | ||
| Kristy L Richards | Q86634383 | ||
| Eric D. Hsi | Q87608965 | ||
| Andrés J M Ferreri | Q88671445 | ||
| Ken H Young | Q96348689 | ||
| Zijun Y Xu-Monette | Q98718521 | ||
| Maurilio Ponzoni | Q101383725 | ||
| April Chiu | Q110194439 | ||
| William W L Choi | Q116791261 | ||
| Alexander Tzankov | Q116791271 | ||
| Aarthi Balasubramanyam | Q116791277 | ||
| Santiago Montes-Moreno | Q37831466 | ||
| Miguel A. Piris | Q37831476 | ||
| Roberto N. Miranda | Q37842538 | ||
| Govind Bhagat | Q38546986 | ||
| Ganiraju Manyam | Q39692890 | ||
| P2093 | author name string | Li Zhang | |
| Ling Li | |||
| Yong Li | |||
| Qin Huang | |||
| Lin Wu | |||
| L Jeffrey Medeiros | |||
| Youli Zu | |||
| Mingzhi Zhang | |||
| Carlo Visco | |||
| Jooryung Huh | |||
| Weiyun Ai | |||
| Xiaoying Zhao | |||
| Wei-min Liu | |||
| Shimin Hu | |||
| P2860 | cites work | Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease | Q24324634 |
| Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma | Q24672476 | ||
| CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells | Q40177590 | ||
| ALK+ lymphoma: clinico-pathological findings and outcome. | Q40818386 | ||
| Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. | Q41474009 | ||
| Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. | Q42277563 | ||
| CD30+ lymphoproliferative disorders | Q42415931 | ||
| Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. | Q42927053 | ||
| The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study | Q44875676 | ||
| Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma | Q46458342 | ||
| Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia | Q46546765 | ||
| Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience | Q46763721 | ||
| LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab | Q46845332 | ||
| Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. | Q50495776 | ||
| EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. | Q51374652 | ||
| CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: A clue to the pathophysiology of clinical regression. | Q52173273 | ||
| Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. | Q53241753 | ||
| The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. | Q53931762 | ||
| Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice | Q57185434 | ||
| Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells | Q73281237 | ||
| CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway | Q77929168 | ||
| High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis | Q79909002 | ||
| Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling | Q80422472 | ||
| A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies | Q82489143 | ||
| A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma | Q24680233 | ||
| Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling | Q27860529 | ||
| Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray | Q28204313 | ||
| A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy | Q28256358 | ||
| The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells | Q28287097 | ||
| Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma | Q28290466 | ||
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers | Q28306431 | ||
| Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy | Q28307991 | ||
| Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation | Q33400803 | ||
| Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study | Q33401346 | ||
| Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. | Q33669371 | ||
| Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas | Q34147803 | ||
| Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte | Q34184706 | ||
| Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. | Q34325760 | ||
| ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project | Q34589970 | ||
| Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab | Q34679166 | ||
| Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation | Q35915899 | ||
| Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma | Q36058584 | ||
| Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone | Q36267666 | ||
| Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study | Q36395599 | ||
| Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con | Q36799606 | ||
| Anaplastic Large Cell Lymphoma. | Q36825791 | ||
| Relation of CD30 expression to survival and morphology in large cell B cell lymphomas | Q37245136 | ||
| Double-hit B-cell lymphomas | Q37813897 | ||
| Anaplastic large-cell lymphoma | Q37919489 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
| B-cell lymphoma | Q4833719 | ||
| P304 | page(s) | 2715-2724 | |
| P577 | publication date | 2013-01-23 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study | |
| P478 | volume | 121 |
| Q89393373 | A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology |
| Q50220287 | A treatment refractory CD30-positive diffuse large B cell lymphoma in the ileal neobladder |
| Q47912434 | Advances in systemic therapy for malignant mesothelioma: future perspectives |
| Q37697843 | Advances in the treatment of hematologic malignancies using immunoconjugates |
| Q40422243 | Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry |
| Q35223221 | Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma |
| Q49282959 | Brentuximab vedotin: clinical updates and practical guidance |
| Q38466350 | CD 30-positive transformed follicular lymphoma: two case reports and literature review. |
| Q47416235 | CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration |
| Q38682195 | CD30 Expression in Pediatric Neoplasms, Study of 585 Cases |
| Q38950501 | CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas |
| Q41411254 | CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma |
| Q42199195 | CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia |
| Q33655362 | CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China |
| Q23921491 | CD30 is a potential therapeutic target in malignant mesothelioma |
| Q35742367 | Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. |
| Q48108703 | Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. |
| Q89777688 | Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL |
| Q92120378 | Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: Case series |
| Q58554680 | Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies |
| Q92062001 | Complete Remission of Relapsed Hodgkin's Lymphoma following Brentuximab Vedotin and Gemcitabine Combination Therapy with Severe Hypotension as Possible Treatment-Related Adverse Event: A Case Report |
| Q55710335 | Different prevalence and clinical outcome of Epstein-Barr virus positive diffuse large B-cell lymphoma between North American and non-Western populations. |
| Q91690485 | Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin |
| Q38710832 | Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy |
| Q35419876 | Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis |
| Q36302961 | Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review |
| Q42051829 | EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. |
| Q35723777 | Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis |
| Q35880791 | Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. |
| Q40796551 | Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions |
| Q38947647 | Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. |
| Q49789150 | Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma |
| Q64917080 | Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells. |
| Q41620612 | Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling |
| Q47584171 | Is CD30 a predictive biomarker for brentuximab vedotin? |
| Q92661439 | Molecular Complexity of Diffuse Large B-Cell Lymphoma: Can It Be a Roadmap for Precision Medicine? |
| Q58010774 | NFκB expression is a feature of both activated B-cell-like and germinal center B-cell-like subtypes of diffuse large B-cell lymphoma |
| Q38315779 | New therapies in non-Hodgkin lymphoma |
| Q38896683 | New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma |
| Q27304386 | Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review |
| Q30434521 | Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma |
| Q41728703 | Occurrence and prognostic relevance of CD30 expression in post-transplant lymphoproliferative disorders. |
| Q57192334 | Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies |
| Q45324330 | Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression |
| Q91148601 | PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Prog |
| Q38245874 | Pathogenesis, diagnosis, and treatment of composite lymphomas |
| Q42230312 | Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. |
| Q33583294 | Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries |
| Q36511738 | Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases |
| Q41564189 | Primary CD30-positive Diffuse Large B-cell Lymphoma in the Superior Vena Cava |
| Q90014799 | Primary diffuse large B-cell lymphoma presenting as acute appendicitis: A report of 2 cases and a literature review |
| Q37725413 | Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting |
| Q38196931 | Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? |
| Q33598637 | Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma |
| Q34649109 | Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan. |
| Q38191191 | Role of CD30 targeting in malignant lymphoma |
| Q64058873 | Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow |
| Q58767936 | Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma |
| Q58011053 | Targeting CD30 expression in diverse Large B-cell lymphoma entities |
| Q54117760 | The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL). |
| Q99711031 | The clinicopathological and molecular features of sinusoidal large B-cell lymphoma |
| Q52955946 | The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas. |
| Q35606714 | The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma |
| Q35607281 | The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma |
| Q90320490 | Using Gene Expression Profiling to Move Beyond MYC/BCL2 Rearrangements in High-Grade Lymphoma |
| Q36681461 | p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function |
Search more.